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CognitionIn recent years there has been a surge of interest and corresponding accumulation of knowledge about the role of
sleep disturbance in schizophrenia. In this review, we provide an update on the current status of experimentally
controlled sleep deprivation (SD) as an experimental medicine model of psychosis, and also consider, given the
complexity and heterogeneity of schizophrenia, whether this (state)model can be usefully combined with other
state or traitmodel systems tomore powerfullymodel the pathophysiology of psychosis.Wepresent evidence of
dose-dependent aberrations that qualitatively resemble positive, negative and cognitive symptoms of schizo-
phrenia as well as deficits in a range of translational biomarkers for schizophrenia, including prepulse inhibition,
smooth pursuit and antisaccades, following experimentally controlled SD, relative to standard sleep, in healthy
volunteers. Studies examining the combination of SD and schizotypy, a trait model of schizophrenia, revealed
only occasional, task-dependent superiority of the combination model, relative to either of the two models
alone. Overall, we argue that experimentally controlled SD is a valuable experimental medicine model of schizo-
phrenia to advance our understanding of the pathophysiology of the clinical disorder and discovery of more ef-
fective or novel treatments. Future studies are needed to test its utility in combinationwith other, especially state,
model systems of psychosis such as ketamine.
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Schizophrenia is a severe psychiatric illness affecting just under 1%
of the populationworldwide (Saha et al., 2005). The symptoms are usu-
ally classified as positive, negative and cognitive, with marked varia-
tions within and between patients over the course of the disorder
(Tandon et al., 2009, 2013; Nasrallah et al., 2011). Its aetiology remains
unknown but is considered to include both genetic and non-genetic risk
factors (Insel, 2010; Keshavan et al., 2008). Existing pharmacological
treatments, usually initiated after a clinical diagnosis, are successful in
alleviating positive symptoms; however, they are not effective for all
patients, do not satisfactorily alleviate negative symptoms or cognitive
deficits, and have numerous unwanted side effects (Miyamoto et al.,
2012). Psychological interventions are beneficial, but they too not are
sufficiently effective for all patients (Lutgens et al., 2017; Polese et al.,
2019). Despite early promises, successful prevention of chronic schizo-
phrenia is not, at least yet, a clinical reality (Malhi, 2019). Thus, there
continues to be a need for a better understanding of schizophreniaience, College ofHealth and Life
K.
ri).
. This is an open access article underpsychopathology as well as more effective treatments for this disorder
and suitable experimental models to aid their discovery.
In this review, we summarise work on the long known association
between schizophrenia and sleep disturbance (review, Waite et al.,
2019). Our focus in on the intriguing finding that sleep loss induces
psychosis-like subjective experiences and associated neurocognitive al-
terations. In particular, we aim to provide an update on whether experi-
mentally controlled sleep deprivation (SD) can serve as an experimental
medicinemodel (review, Ettinger andKumari, 2015), thereby addressing
the above-mentioned need for experimental models to aid in the under-
standing of schizophrenia pathology and the development of treatments.
Additionally, we evaluate, given the complexity and heterogeneity of
schizophrenia, whether SD, a state model, can be combined with other
state or trait models of psychosis to more powerfully capture the patho-
physiology of psychosis.
Before turning to these specific issues,wefirst discuss the general ra-
tionale of experimental models of schizophrenia and the use of related
biomarkers.
1.1. Experimental models of schizophrenia and related biomarkers
As outlined above, there is a significant unmet clinical need for
new pharmacological treatments that adequately treat all symptomthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ment of antipsychotic drugs has been slow in the past years, with
pharmaceutical companies facing difficulties in terms of high attri-
tion rates of new compounds in surrogate patient populations in
Phase II and III (Kola and Landis, 2004). This means that a number
of compounds, despite showing promise in preclinical animal
models and yielding good safety and tolerability data in first-in-
man studies, do not translate into clinically effective treatments for
patients.
Approaches to circumvent these problems include the use of exper-
imentalmedicinemodels with better predictive power, i.e. the ability to
discriminate between compounds likely to succeed or fail in later clini-
cal studies (Dourish and Dawson, 2014). Numerous models have been
proposed and tested, both in humans and in non-human animals.
Approaches focussed exclusively on humans include the study of psy-
chometric schizotypes, i.e. people with high scores on schizotypy ques-
tionnaires. Schizotypy refers to a set of personality traits thought to
reflect, at subclinical level, the expression of schizophrenia liability
(Grant et al., 2018). High schizotypy is associated with schizophrenia-
like deficits in cognition and brain function, and has been shown to be
a predictor of antipsychotic drug effects on cognitive and oculomotor
biomarkers (Ettinger et al., 2014). Other human model approaches in-
clude the study of performance-based groups, such as individuals with
low prepulse inhibition (PPI), a schizophrenia biomarker known to be
sensitive to pharmacological influences (Swerdlow et al., 2008).
Experimental models implemented only in non-human laboratory
animals, on the other hand, include lesions or interventions aimed at so-
cial neurodevelopmental processes, such as isolation rearing (Geyer
et al., 1993). However, such models may be criticised for their lack of
translation across species, which represents a serious drawback in
drug development. Therefore, in order to best bridge preclinical (non-
human animal) and human studies, particular attention has been paid
to developing and refining truly translational, cross-species models
(Geyer et al., 2012). Such models include pharmacological challenges,
such as ketamine, or experimentally controlled SD, as will be described
in more detail further below.
Ketamine is an uncompetitive antagonist at the N-methyl-D-
aspartate (NMDA) receptor. It is widely used as an anaesthetic and an-
algesic, but in low doses reproducibly and convincingly induces
psychosis-like experiences in healthy individuals and exacerbates
symptoms in schizophrenia patients (Krystal et al., 1994; Lahti et al.,
2001). Ketamine also induces some (Krystal et al., 1994; Steffens et al.,
2016), but not all (Steffens et al., 2018), of the key cognitive-motor def-
icits observed in schizophrenia. The psychotomimetic effects of the sub-
stance are in line with the hypothesised role of the glutamate system in
schizophrenia (Javitt et al., 2012).
Undoubtedly, these experimental models have been extremely
fruitful in (i) generating hypotheses concerning the aetiology and path-
ophysiology of schizophrenia and (ii) providing test beds for antipsy-
chotic drug development. Nevertheless, they may be criticised for a
number of reasons, including (i) incompleteness in inducing the broad
spectrum of schizophrenia symptoms (Carhart-Harris et al., 2013), (ii)
lack of cross-species translation in the case of schizotypy in humans or
isolation rearing in animals, and (iii) the problem of “receptor tautol-
ogy”, as in the case of dopamine agonist models such as amphetamine
(Geyer et al., 2012). Therefore, further research is needed in order to de-
velop and refine more convincing experimental models that can be ap-
plied both in laboratory animals and human volunteers.
Importantly, it should be noted that experimental models are usu-
ally studied in combination with biomarkers as surrogate endpoints
(Dourish and Dawson, 2014). In animals, biomarkers are in fact the
key focus of research, and in humans they are typically studied in addi-
tion to, and complementing, subjective measures. A biomarker is de-
fined as “a characteristic that is objectively measured and evaluated as
an indicator of normal biological processes, pathogenic processes, or
pharmacologic responses to a therapeutic intervention” (NationalInstitutes of Health Biomarkers Definitions Working Group). Given
that cognitive deficits have been reproducibly observed in schizophre-
nia (Schaefer et al., 2013), measures of cognition and brain function as
well as related motor and perceptual tasks have been frequently used
as biomarkers. The most promise may be ascribed to those biomarkers
that can be studied across species.
1.2. Sleep disturbance in schizophrenia: clinical and epidemiological
evidence
As will be argued below, experimentally controlled SD may repre-
sent a suitable model of psychosis. This argument is grounded in find-
ings of sleep disturbances in schizophrenia, which will be summarised
briefly in this section.
Sleep disturbance, assessed using face-to-face interviews, sleep
diary, actigraphy or polysomnography, has been commonly reported
in schizophrenia, with up to 80% of patients displaying disturbances in-
cluding delays in falling asleep, difficulties in initiating as well as main-
taining sleep, a reduction in total sleep time, multiple night-time
awakenings, non-restorative sleep, and decreased stage 4 sleep, slow
wave sleep and duration and latency of rapid eye movement (review,
Chan et al., 2017). Sleep dysfunction is also observed more commonly
in people at a high risk for psychosis (review, Davies et al., 2017), espe-
cially in those with suspiciousness and perceptual abnormalities
(Goines et al., 2019), and in association with psychotic-like symptoms
in the general population (Andorko et al., 2017; Reeve et al., 2015). Fur-
thermore, childhood sleep disturbance predicts the risk of later (adoles-
cent) psychotic experiences (Thompson et al., 2015), with recent data
also showing a genetic overlap between the risk for schizophrenia and
sleep disturbance in children (Reed et al., 2019; Taylor et al., 2015).
Some of the above-mentioned sleep disturbances are attenuated by
antipsychotic treatment while others are acutely exaggerated by anti-
psychotic withdrawal or relate to the duration of illness (Chouinard
et al., 2004; Chan et al., 2017). However, evenmedication-naïve schizo-
phrenia patients show abnormalities in sleep continuity (shorter total
sleep time, longer sleep onset latency and total awake time, decreased
sleep efficiency) compared to healthy controls, although they may not
significantly differ from healthy controls in sleep architecture (Chan
et al., 2017).
Overall, these findings can be taken to suggest that experimental
manipulations that disrupt sleep continuitymay be particularly relevant
to developing SD as a valid experimental medicine model of psychosis.
2. Controlled SD as an experimentalmedicinemodel of schizophrenia
In the following, wewill review evidence of the controlled SDmodel
of schizophrenia. We will first describe findings from studies of the ef-
fects of sleep loss on schizophrenia-related psychopathology, before
highlighting some of the key findings with regards to the effects of SD
on electrophysiological and cognitive biomarkers of schizophrenia.
2.1. SD and schizophrenia psychopathology
There is empirical evidence of a strong association between sleep
disturbance and symptom severity in people with schizophrenia (re-
view, Waite et al., 2019). Particularly relevant within the context of
this review are findings showing that objective indices of poor sleep
quality predict the onset of positive symptoms at one year in adolescents
(e.g. Lunsford-Avery et al., 2015) while both objectively-assessed and
subjectively-reported poorer sleep quality and efficiency predict next-
day increased severity on many symptom dimensions, including audi-
tory hallucinations, paranoia, and delusions, in schizophrenia patients
(Mulligan et al., 2016).
For experimentally controlled SD to be a valid experimental medi-
cine model of schizophrenia, it must be capable of inducing alterations
in perceptions, thoughts and behaviour that are qualitatively similar to
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number of healthy volunteer studies. Early studies (Kollar et al., 1969;
Luby et al., 1962; West et al., 1962) reported SD to cause hallucinations
(e.g., episodic blurred vision, tingling sensations in the skin or sensation
of being detached, humming or ringing noises in the ears), disorganiza-
tion (e.g., overt confusion, disorientation), and negative symptoms
(e.g., disinterest in the outsideworld, a tendency towithdraw). Paranoia
(Kahn-Greene et al., 2007) and an increase in formal superstitious
thinking (Killgore et al., 2008) have been reported after 55 h of con-
trolled SD. More recently, we (Petrovsky et al. 2014) reported increases
of small-to-moderate magnitude in self-ratings of perceptual distortion
(positive symptoms), anhedonia (negative symptoms) and cognitive
disorganization (thought disorder) after just 24-h of controlled SD. Sim-
ilar observations were made in three later studies (Faiola et al., 2018;
Meyhöfer et al., 2017b, 2019) involving partially overlapping samples
(but no overlap with Petrovsky et al. 2014 sample). Even partial SD (re-
stricted to 4-hour sleep for 3 nights), compared to standard sleep, has
been shown to cause significant increases in self-ratings of paranoia,
hallucinations, and cognitive disorganization, negative affect, negative
self and other cognitions, and worry (Reeve et al., 2018). The length of
SD, however, is important as observable psychotic symptoms appear
to require a longer period (N100 h) of SD to manifest (Berger and
Oswald, 1962; Coren, 1998; Luby et al., 1962; West et al., 1962).
It is also important to highlight that despite limited clinical focus and
empirical investigations of possible associations between sleep (conti-
nuity or architecture) and negative symptoms in people with schizo-
phrenia, the findings from healthy volunteer research suggest that
experimentally controlled SD can be used to model positive, negative
and cognitive dimensions of schizophrenia psychopathology.
2.2. SD and schizophrenia biomarkers
Here, we will review research that has investigated the effects of SD
on biomarkers of schizophrenia. The key rationale is that the SD model
is validated to the extent that established biomarkers of schizophrenia
are reproducibly induced by experimentally controlled SD. Such studies,
if successful, provide the basis for (i) using such biomarkers in drug de-
velopment and (ii) further mechanistic studies into the pathophysiol-
ogy of schizophrenia.
2.2.1. Prepulse inhibition
Prepulse inhibition (PPI) refers to a reduction in response to a star-
tling pulse when it follows a weak non-startling prepulse with a short
stimulus onset asynchrony (Graham, 1975). It is considered a cross-
speciesmeasure of sensorimotor gating that helps to protect the process-
ing of the initial stimulus (the prepulse) (Braff and Geyer, 1990). There
are numerous reports of reduced PPI in people with schizophrenia (re-
views, Braff, 2010; Swerdlow et al., 2008), including unmedicated first-
episode patients (Kumari et al., 2007; Ludewig et al., 2003). Additionally,
lower PPI has been found in their first-degree relatives (Cadenhead et al.,
2000; Kumari et al., 2005), in patientswith schizotypal personality disor-
der (Cadenhead et al., 2000, 1993), and individuals with a high-risk sta-
tus (De Koning et al., 2014; Ziermans et al., 2011), suggesting it may be
one of the robust endophenotypes for schizophrenia (Greenwood et al.,
2019a). PPI has also been studied widely as a translational surrogate
marker in the development of antipsychotic and pro-cognitive drugs
(Swerdlow et al., 2008).
In rodents, SD causes a marked PPI disruption (Chang et al., 2014;
Frau et al., 2008; Liu et al., 2011; Öz et al., 2018). Furthermore, confirming
the schizophrenia-specificity of SD effect on PPI, this disruption is revers-
ible with antipsychotic compounds haloperidol, clozapine and risperi-
done but not with the anxiolytic diazepam or the antidepressant
citalopram (Frau et al., 2008). Interestingly, PPI in sleep-deprived rats
also improves with orexin A, which is a neurotransmitter released from
lateral hypothalamus and implicated in the modulation of sleep/wake-
fulness system (Öz et al., 2018). This finding, taken together with theobservations of lower orexin A in schizophrenia patients (on average)
relative to healthy controls and an inverse association between plasma
orexin A and negative and disorganized symptoms in patients (Chien
et al., 2015), suggests a role for orexinA in advancing schizophrenia ther-
apeutics, especially for patients or at-risk groups with prominent sleep
disturbance.
Petrovsky and colleagues (2014) extended the finding of SD-induced
PPI disruption in rats to healthy humans. Specifically, their study revealed
a significant reduction in PPI following a night (24-h) of SD, compared to
that seen after a normal night sleep. A very recent study (Meyhöfer et al.,
2019) using similar methods to that used by Petrovsky and colleagues
(2014) also observed a reduction in PPI following a 24-hour SD, albeit
with a smaller effect size, most likely because the sample in that study
was predominantly female with no control for menstrual cycle status in
the design, and half of the sample had higher levels of schizotypy
which itself was associated with lower PPI. Short sleep duration (b4 h
in the preceding night) has also been found to be associated with lower
PPI in post-partum women (Comasco et al., 2016), a period also associ-
ated with emergence of psychosis or worsening of symptoms (Jones
et al., 2014). Overall, both animal and healthy human volunteer studies
show PPI-disruptive effects of SD.
2.2.2. Antisaccade and smooth pursuit eye movements
Eye movements have been studied in schizophrenia and other psy-
chiatric disorders for over a hundred years (Diefendorf and Dodge,
1908; Klein and Ettinger, 2008). Eye movement (or oculomotor) tasks
are highly suitable to provide schizophrenia biomarkers, as tasks typically
are short, key parameters can be manipulated experimentally (Barnes,
2008; Hutton, 2008), measurement is highly reliable (Meyhöfer et al.,
2016), the neural mechanisms of eye movements are well understood
(Hutton and Ettinger, 2006; Lencer and Trillenberg, 2008) and perfor-
mance is sensitive to pharmacological influences (Reilly et al., 2008).
Two experimental tasks that provide particularly well validated
schizophrenia biomarkers are the smooth pursuit eye movement
(SPEM) and antisaccade (AS) tasks.
SPEM occurs when the participant follows a slowly moving visual
target with their eyes, while keeping the head still. SPEM is supported
by a network of visual-motor structures, including visual areas V1 and
V5, posterior parietal cortex, frontal and supplementary eye fields,
basal ganglia and cerebellum (Lencer and Trillenberg, 2008). SPEM im-
pairments in schizophrenia include a reduction in gain, i.e. the velocity
with which the eyes follow the target, and an increase in saccades dur-
ing pursuit (O'Driscoll and Callahan, 2008).
In the AS task, an automatic saccade, i.e. a rapid eye movement that
serves to redirect gaze, towards a sudden-onset peripheral stimulus has
to be inhibited. Instead, a saccade in the opposite direction of the stim-
ulus has to be performed, making the task a prominentmeasure of pre-
potent response inhibition (Hutton and Ettinger, 2006), a central
function of cognitive control (Miyake et al., 2000). Antisaccade perfor-
mance is supported by a fronto-parieto-striatal network (Munoz and
Everling, 2004). Patients with schizophrenia display a highly reproduc-
ible increase in the rate of direction errors, i.e. saccades to the peripheral
target (Hutton and Ettinger, 2006).
Effects of SD on AS performance have been studied in a small num-
ber of studies (for review, see Meyhöfer et al., 2017a). The inhibitory
performancemeasure of direction error rates has been shown to be im-
paired, i.e. increased, following SD, compared to performance after nor-
mal sleep at the same time of day (Bocca et al., 2014; Meyhöfer et al.,
2017a; Meyhöfer et al., 2017b), but other studies have failed to find
this effect (Crevits et al., 2003; Gais et al., 2008; Zils et al., 2005). Another
study showed that partial SD, when participants were allowed to sleep
only between 2 am and 7 am, caused increased AS direction errors (Lee
et al., 2015).
Regarding SPEM, the majority of studies have shown SD-induced
impairments (De Gennaro et al., 2000; Fransson et al., 2008; Porcu
et al., 1998; Tong et al., 2014; Meyhöfer et al., 2017a, 2017b), although
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Steveninck et al., 1999).
Overall, therefore, the SD-induced impairments in SPEM and AS con-
tribute to validating this putative model of psychosis. It should be noted,
however, that the specificity of the SDmodelwith regards to oculomotor
biomarkers is undermined by findings of prosaccade impairments, such
as increased latency or reduced velocity. These impairments are likely
due to fatigue, but are not always compatible with the profile of impair-
ments in schizophrenia, as discussed previously (Meyhöfer et al., 2017a).
SD thus has effects on oculomotor control beyond schizophrenia-like al-
terations of relevant biomarkers, a pattern that has to be considered
when interpreting findings from this model.
2.2.3. Attention and working memory
In healthy humans, SD has been shown to be detrimental to perfor-
mance on attentional tasks in a dose-dependentmanner, corresponding
with the amount of time awake (review, Krause et al., 2017). The perfor-
mance deteriorations are typically expressed as errors of omission and
unstable task performance (Belenky et al., 2003; Durmer and Dinges,
2005; VanDongen et al., 2003), with broadly similar attentional impair-
ments following SD or restriction also seen in rodents (e.g. Oonk et al.,
2015). Working memory, which like attention is critically important
for ongoing goad-directed behaviour, is also susceptible to SD, both in
humans (e.g. Drummond et al., 2012; Faiola et al., 2018; Reeve et al.,
2018; Turner et al., 2007) and rodents (e.g. Xie et al., 2015).
It is possible that SD-induced working memory impairment in
humans, especially in the verbal domain, may be, at least partially, me-
diated by anxiety, given that increased anxiety is commonly seen fol-
lowing SD (meta-analysis, Pires et al., 2016), and anxiety is known to
be associatedwith poor or unstable attention andworkingmemory per-
formance (reviews, Blasiman and Was, 2018; Moran, 2016). This may
be explained by the use of attentional and cognitive resources (espe-
cially the phonological loop) by worry-related thoughts, leaving less-
than-optimal resources available for task performance (Derakshan and
Eysenck, 2009). Importantly, anxiety is also a common symptom in
young people at clinical high risk for psychosis (McAusland et al., 2017).
The findings of SD-induced impairments in attention and working
memory fit nicely with the pattern of attentional (Nuechterlein et al.,
2015) and working memory deficits (Greenwood et al., 2019a; review,
Lett et al., 2014) commonly seen in people with schizophrenia, with
even poorer performance in sub-groups with sleep disturbance (Göder
et al., 2004). Furthermore, the brain changes found to accompany nega-
tive effects of acute SD on attention andworkingmemory tasks (review,
Krause et al., 2017) overlap considerably with brain dysfunctions impli-
cated in schizophrenia (Keshavan et al., 2008; Mwansisya et al., 2017).
2.2.4. Cognitive control
Cognitive control, or executive function, refers to a set of general-
purpose control mechanisms, often linked to prefrontal cortex function,
that dynamically regulate thoughts and behaviour (Miller and Cohen,
2001). Cognitive control allows the pursuit of goals, while retaining
the flexibility to adapt behaviour to changing situational demands. Ac-
cording to an influential model (Miyake et al., 2000), cognitive control
comprises three dimensions, viz. inhibition, shifting and updating.
Inhibition refers to the ability to suppress dominant but situationally
inappropriate thoughts or actions. Inhibitory impairments have fre-
quently been observed following controlled SD (review, Cassé-Perrot
et al., 2016). Specifically, we observed an increased rate of commission
errors on the go/nogo task (Faiola et al., 2018). Further support for ef-
fects on inhibition comes from studies of antisaccade performance,
which have shown increased rates of direction errors on this task (see
above). Additionally, and given the putative link between (deficient) in-
hibition and impulsivity (Aichert et al., 2012; Cyders and Coskunpinar,
2011), studies of impulsive and risky choices, a domain of decisionmak-
ing linked to inhibition and impulsivity, are also relevant, and SD effectsin this domain have also been observed (review, Cassé-Perrot et al.,
2016).
Shifting tasks index mental flexibility, i.e. the switching between
tasks or task demands. Consistent with findings of impaired switching
performance in schizophrenia (review, Schaefer et al., 2013), there is
evidence that SD impairs performance on tasks involving flexibility
(e.g. Nilsson et al., 2005; Slama et al., 2018).
Finally, deficits in updating,which refer to the activemanipulation of
information in working memory, have been observed following SD, as
mentioned earlier.
2.2.5. Memory and language
There is robust evidence from rodent studies for a role of sleep in
learning and memory (Rasch and Born, 2013) as is also the case in
healthy humans, especially for hippocampus-dependent learning and
memory (review, Krause et al., 2017). For example, 35-hour (one night)
SD impairs free recall of verbalmaterials, accompaniedwith reducedme-
dial temporal lobe activity (Drummond et al., 2000). Episodic memory is
reported to be disrupted by just 24-h of SD (Chuah et al., 2009). Such
findings are highly pertinent to schizophrenia patients who typically
show deficits, with a large effect size, on such hippocampal activity de-
pendent tasks (Reichenberg andHarvey, 2007; Greenwood et al., 2019b).
Performance on language tasks that involve sustained attention and
higher-level processing (e.g., reading comprehension) too shows a de-
cline following (38-h in this case) SD (Pilcher et al., 2007). Although
the effect of SD on language cannot be tested in animals for obvious rea-
sons, such findings are important for the validity of any experimental
medicine model of schizophrenia, given that there is a genetic overlap
between schizophrenia and dyslexia and a large proportion of schizo-
phrenia patients display marked deficits (over the background of defi-
cits in other cognitive domains) in reading skills (review, Whitford
et al., 2018).
2.2.6. Social cognition
There is emerging literature, especially from studies of healthy volun-
teers, for SD to impair emotional and social responding (review, Krause
et al., 2017). For example, evenpartial SD (4versus 8 hour sleep) reduces
responsiveness to facial affect (Schwarz et al., 2013). Partial and total SD
have negative impact on response to emotional pictures (Alfarra et al.,
2015), especially to pleasant pictures (Pilcher et al., 2015). SD also nega-
tively impacts self-regulation, including emotional regulation, and social
monitoring (i.e., perception and interpretation of cues relating to self and
others) (review, Dorrian et al., 2019). These observations further but-
tress the validity of SD as a useful model of schizophrenia. Social cogni-
tion deficits have gained prominence over the last decade and are now
considered to represent an endophenotype (Greenwood et al., 2019b;
Millard et al., 2016; Tikka et al., 2019) and an important treatment target
for schizophrenia (Javed and Charles, 2018).
3. Combining SDwith othermodels of psychosis: a sensible strategy?
As outlined in the previous sections, SD has been found to mimic
central dimensions of psychosis psychopathology and several key bio-
markers. As such, SD represents a convincing and promising experi-
mental medicine model, with perhaps a wider spectrum of effects
than other experimental models (Carhart-Harris et al., 2013). However,
it should be acknowledged that the effects of SD on both psychopathol-
ogy and biomarkers tend to be of only small-to-medium effect size,
smaller than those seen in schizophrenia (Schaefer et al., 2013). Drug
development studies may wish to test novel compounds in early
human studies with greater power to detect alleviating effects.
Therefore, it may be proposed that a combination of the SD model
with other models of schizophrenia may be a fruitful strategy. Such
work has to place the safety and well-being of participants first; how-
ever, certain combinations of model approaches are both feasible and
promising. One such combination concerns the state model of SD with
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fects of 24-hours SD and positive schizotypy (the Unusual Experiences
subscale of the Oxford Liverpool Inventory of Feelings and Experiences,
O-LIFE, short version; Mason et al., 2005).
In a first analysis (Meyhöfer et al., 2017b), we observed that the pri-
mary measure of the smooth pursuit biomarker (see above), the pursuit
velocity gain, showed an interaction between SD andpositive schizotypy
for the faster of two target frequencies, i.e. 0.4 Hz, a stimulus that has fre-
quently been studied in schizophrenia (O'Driscoll and Callahan, 2008).
The interaction indicated that performance was lower after SD than
the control night for schizotypes, but not for controls.
In a further analysis of data from that study (Meyhöfer et al., 2019),
we observed effects of both SD (p = .07) and schizotypy (at 60 and
120 ms stimulus onset asynchrony, but not at 30 ms) on PPI, but no in-
teraction. We interpret this pattern of findings to indicate that SD and
schizotypy affect PPI via different neural mechanisms.
Finally, we analysed data from a comprehensive cognitive battery
from that study, including response inhibition, working memory,
sustained attention, verbal learning, problem solving and verbal fluency
(Faiola et al., 2018).We found that SD adversely affected response inhi-
bition (go/nogo task) and performance on an n-back working memory
task, but did not interact with schizotypy.
To the best of our knowledge, no studies are available in humans
that combine SD with pharmacological models such as ketamine (for
rodent work, see e.g. Takahashi et al., 1984).
Overall, therefore, data from combinations of SD with other models
of psychosis is scant, and further work is desperately needed. Such
work has to carefully balance ethical implications with knowledge
gain, but has the potential to contribute significantly to our understand-
ing of the pathophysiology of schizophrenia and may provide useful
testbeds for drug development. Future studiesmay also benefit from di-
rectly comparing models (for rodent work, see e.g. Campbell and
Feinberg, 1999), in order to identify which aspects of psychosis phe-
nomenology, cognition and brain function are best modelled by which
approach. Such head-to-head comparisons may then pave the way for
carefully justified combinations of experimental interventions.
4. Conclusions and future directions
In this review, we discussed the intriguing, psychosis-like effects of
SD in humans. This work is of interest, as it may help to fill the need
for experimental models to aid in the understanding of schizophrenia
pathology and the development of treatments.
Overall, the evidence to date demonstrates wide-ranging effects of
experimentally controlled SD, including aberrations that are qualita-
tively similar to positive, negative and cognitive symptoms of schizo-
phrenia. It also produces deficits in a range of electrophysiological and
cognitive biomarkers for schizophrenia. Of significant relevance here
are the findings of SD-induced impairments that closely mirror those
found in people with schizophrenia in the domains of sensorimotor gat-
ing, inhibition, attention,workingmemory, executive function,memory,
language and social cognition.We, therefore, assert that SD qualifies as a
useful schizophrenia model system incorporating perhaps more facets
of schizophrenia than some other models (mentioned earlier) and
which, when used in combinationwith known biomarkers, can advance
our understanding of schizophrenia psychopathology and therapeutics.
Regarding our evaluation of the potential of the SDmodel to perform
better when used in combination with other models, there were insuf-
ficient data. The available studies examined a combination of SD and
schizotypy and revealed only occasional task-dependent superiority of
the combination model, relative to either of the two models alone.
There was no evidence for an additive effect, with the effect of SD
seen in those with high, but not low, schizotypy in one measure, viz.
SPEM gain, that itself was not significantly affected by schizotypy in
that study (Meyhöfer et al., 2017b). Further studies are needed to exam-
ine the dose-dependent effects of SD on schizophrenia psychopathologyand relevant biomarkers not only in combination with pharmacological
models (e.g., SD × ketamine interaction) but also with environmental
(e.g., SD × history of trauma) and genetic models (e.g., SD × family his-
tory/risk genes) of schizophrenia.
For example, it would be of interest to examine the effects of acute SD
on schizophrenia biomarkers as a function of genetic load for schizophre-
nia. Genetic load may be indexed by family status, i.e. having a relative
with schizophrenia or not, or by polygenetic risk score (PRS) for schizo-
phrenia. It may be expected that individuals with a greater genetic load
for schizophrenia show stronger effects of SD on schizophrenia bio-
markers. Additionally, environmental factors such as urban vs. rural up-
bringing or the level of noise exposure may be variables that mediate
effects of SD; again, this remains to be investigated. Finally, research on
the SDandketaminemodels of schizophrenia hasprogressed largely inde-
pendently of each other. It would be of great interest, however, to directly
compare the effects of these two interventions on a battery of biomarkers
with each other and to explore, carefully, their interactive effects in sleep
deprived individuals who are additionally exposed to low, psychotomi-
metic doses of ketamine. Such a designwould allow to identify both over-
lapping and unique mechanisms of these different models of psychosis.
Despite the intriguing, and consistent effects of SDon schizophrenia-
related biomarkers, open questions remain. A particularly pertinent
issue is that of the neural mechanisms of the observed effects. In
humans, studies using functional magnetic resonance imaging (fMRI)
are needed in order to elucidate the macroscopic brain functional
changes that accompany SD effects on primary schizophrenia bio-
markers such as PPI or eye movements. Studies using resting state
fMRI have pointed to dysregulation of functional connectivity following
SD. These include (i) reduced integration within functional networks,
(ii) reduced segregation between networks and (iii) an increase in
global blood oxygen dependent (BOLD) signal (Chee and Zhou, 2019).
Other evidence on the neural effects of SD comes frommolecular imag-
ing techniques. Using positron emission tomography (PET) and the D2/
D3 dopamine receptor ligand [11C] raclopride, Volkow et al. (2008)
showed that one night of SD caused a reduction in binding in striatum
and thalamus. This reduction was interpreted as increased dopamine
levels following SD. Interestingly, the magnitude of the binding corre-
lated with SD-induced impairments in visual attention and working
memory. In addition to dopamine, the serotonergic system is also af-
fected by SD (e.g., Elmenhorst et al., 2012). Overall, more research is
needed to pinpoint the neuralmechanisms – both at functional andmo-
lecular levels – of the effects of SD on schizophrenia biomarkers. It will
be of particular interest to combine such measures with antipsychotic
treatments with dopaminergic and serotonergic action.
A limitation of the SD model concerns its somewhat limited specific-
ity. As we have argued previously (Meyhöfer et al., 2017a), SD does not
selectively affect schizophrenia biomarkers, but has pervasive effects
on cognitive and oculomotor function, in line with its effects on fatigue.
Accordingly, SD has been investigated as a cognitive challenge model
with possible applications to disorders other than schizophrenia (e.g. de-
mentia; Cassé-Perrot et al., 2016). However, fatigue-like effects of SD, in
addition to its schizophrenia-relevant effects, may also be profitably
exploited to model comorbid depression and schizophrenia, given that
fatigue is one of the most prominent symptoms of depression (Baldwin
and Papakostas, 2006) and depression is often present in schizophrenia,
especially during the acute stages (Upthegrove et al., 2010). Similarly, in-
creased anxiety following SD can be utilised to model anxiety that is
commonly present and associated with more severe symptoms in
young people at a high risk for psychosis (McAusland et al., 2017).
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